Business Context and Reporting Period
GX Acquisition Corp. filed this Form 8-K on April 16, 2021, reporting an extension proposal related to its pending business combination with Celularity Inc., an allogeneic cellular therapy company. The filing concerns GX, the SPAC registrant, rather than a periodic financial report of Celularity.
Material Event
- GX announced that it would seek stockholder approval to extend the deadline for completing its initial business combination from May 23, 2021 to July 31, 2021.
- The extension is intended to provide additional time to complete the SEC review process, conduct an accounting review of GX’s public and private warrants, hold the required stockholder meetings, satisfy closing conditions, and consummate the Celularity Business Combination.
- GX and Celularity entered into a definitive merger agreement in January 2021. If completed, Celularity would combine with GX and become a publicly listed company.
Financial Metrics and Liquidity
The filing does not provide current-period or prior-period revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics. It also does not state the amount of any proposed financing or PIPE Investment.
Guidance, Outlook, Risks, and Unusual Items
- GX’s board indicated that there may not be sufficient time before May 23, 2021 to complete the warrant accounting review, obtain required approvals, and close the transaction.
- The SEC had publicly raised accounting and reporting considerations regarding warrants issued by special purpose acquisition companies, prompting GX to begin a complete review of its warrant accounting treatment.
- Completion of the extension and the business combination remains subject to stockholder approval, SEC review, satisfaction of merger agreement closing conditions, and other customary requirements.
- Key disclosed risks include failure to complete the business combination or PIPE Investment; Celularity’s ability to develop therapies, conduct clinical trials, obtain regulatory approvals, expand manufacturing, obtain funding, and protect intellectual property; competition; litigation and regulatory proceedings; changes in laws; and COVID-19-related effects.
- The filing contains forward-looking statements regarding the transaction, Celularity’s future performance, development programs, capital requirements, operations, and prospects. Actual results may differ materially.
Important Facts to Verify
- Whether GX stockholders approved the extension through July 31, 2021.
- Whether the SEC declared the relevant Form S-4 registration statement effective and whether subsequent amendments were filed.
- Whether GX completed the warrant accounting review and resolved any related accounting implications.
- Whether required stockholder approvals, closing conditions, and any PIPE financing were completed.
- Whether the Celularity Business Combination ultimately closed and the date on which Celularity became publicly listed.